Prospects for the prevention of HPV-associated cancer

1. WHO. IARC Monographs on the evaluation of carcinogenic risks to humans. IARC Monographs, Volume 10(B). 2012.
2. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., Ball L.A., eds. Virus taxonomy: 8th ICTV report of the international committee on taxonomy. Elsevier, Academic Press; 2005. 1259 p.
3. Castellsague X, de Sanjose S, Aguado K. et al. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25(Suppl. 3): C1-230.
4. Egawa K. Do human papillomaviruses target epidermal stem cells? Dermatology. 2003; 207(3): 251-4.
5. Herfs M., Vargas S.O., Yamamoto Y., Howitt B.E., Nucci M.R., Hornick J.L. et al. A novel blueprint for “top down” differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J. Pathol. 2013; 229(3): 460-8.
6. Herfs M., Yamamoto Y., Laury A., Wang X., Nucci M.R., McLaughlin-Drubin M.E. et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl. Acad. Sci. USA. 2012; 109(26): 10516-21.
7. Potten C.S. Cell replacement in epidermis (keratopoiesis) via discrete units of proliferation. Int. Rev. Cytol. 1981; 69: 271-318.
8. Schmitt A., Rochat A., Zeltner R., Borenstein L., Barrandon Y., Wettstein F.O., Iftner T. The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J. Virol. 1996; 70: 1912-22.
9. Steben M., Tan Thompson M., Rodier C. Review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J. Obstet. Gynaecol. Can. 2018; 40(12): 1635-45.
10. Мальцева Л.И., Ахметзянова А.В., Фаррахова Л.Н., Нигматуллина Н.А. Цервикальная интраэпителиальная неоплазия: возможности диагностики и лечения. Практическая медицина. 2012, 9: 52-5. [Cervical intraepithelial neoplasia: diagnostic and treatment options 2012, 09 (12). (in Russ.)]
11. Bruni L. et al. IARC/ICO Information Centre on HPV and Cancer (HPV Information Centre. Human papillomavirus and related diseases in Russian Federation. Summary Report 10 December 2018. Availadle at: http://www.hpvcentre.net/statistics/reports/RUS.pdf?t=1548009998402
12. Грецова О.П., Костин А.А., Самсонов Ю.В., Петрова Г.В., Простов М.Ю., Простов Ю.И. Заболеваемость и смертность от злокачественных новообразований, ассоциированных с вирусом папилломы человека. Исследования и практика в медицине. 2017; 4(3): 33-50. [Gretsova O.P. Kostin A.A., et al. Morbidity and mortality from malignant neoplasms associated with human papillomavirus. Res practice in medicine. 2017; 4 (3): 33-50. (in Russ.)]
13. Greer C.E., Wheeler C.M., Ladner M.B., Beutner K., Coyne M.Y., Liang H. et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol. 1995; 33(8): 2058-63.
14. Sturegard E., Johansson H., Ekstrom J., Hasson B.G., Johnsson A., Gustafsson E. et al. Human papillomavirus typing in reporting condyloma. Sex. Transm. Dis. 2013; 40(2): 123-9.
15. Castellsague X., Cohet C., Puig-Tintore L.M., Acebes L.O., Salinas J., San Martin M. et al. Epidemiology and cost of treatment of genital warts in Spain. Eur. J. Public Health. 2009; 19(1): 106-10.
16. Desai S., Wetten S., Woodhall S.C., Peters L., Hughes G., Soldan K. Genital warts and cost of care in England. Sex. Transm. Infect. 2011; 87(6): 464-8.
17. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infectious Diseases. 2013; 13: 39.
18. HPV and Men - Fact Sheet Centers for Disease Control and Prevention (СDС), February 4, 2015. [Папилломавирусная инфекция (ВПЧ) у мужчин. Вопросы и ответы. Официальная позиция CDC (Национального центра по контролю и профилактике заболеваний), США, 2015 г.]
19. Centers for Disease Control and Prevention (CDC). Human papillomavirus–associated cancers - United States, 2004-2008. MMWR Morb. Mortal. Wkly Rep. 2012; 61: 258-61.
20. Zhou J. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185(1): 251-7.
21. Kirnbauer R. Papillomavirus L. major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 1992; 89(24): 12180-4.
22. Human Papillomavirus (HPV) Vaccine Merck Sharp & Dohme. July 2018. (Электронный ресурс). Available at: https://www.msdmanuals.com/professional/infectious-diseases/immunization/human-papillomavirus-hpv-vaccine
23. Еженедельный эпидемиологический бюллетень. 2014; 43: 89, 465-92. Вакцины против папилломавирусной инфекции человека: документ по позиции ВОЗ, октябрь 2014. (Электронный ресурс). Available at: https://www.who.int/immunization/policy/position_papers/PP_HPV_Russian_Oct2014.pdf
24. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. U.S. Food & Drug Administration; 5 October 2018. (Электронный ресурс). Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm
25. Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J. et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2014;63(RR-05): 1-30.
26. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) “Updated Recommendations on Human Papillomavirus (HPV) vaccine and clarification of minimum intervals between doses in the HPV immunization schedule”. July 2016.
27. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) “Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised population.May 2017.
28. Schellenbacher C., Roden R.B., Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017; 231: 166-75.
29. Center for Disease Control and Prevention. Recommended Immunizations for Children 7-18 Years Old, 2018. Janaury 17, 2018 CS289048-A. (Электронный ресурс). Available at: https://www.cdc.gov/vaccines/schedules/downloads/teen/parent-version-schedule-7-18yrs.pdf
30. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007; 356(19): 1915-27.
31. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007; 356(19): 1928-43.
32. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A. et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369(9574): 1693-702.
33. Lehtinen M., Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017 Aug; 7(8): e015867.
34. Patel C., Brotherton J.M., Pillsbury A., Jayasinghe S., Donovan B., Macartney K., Marshall H. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018; 23(41).
35. Korostil I., Ali H., Guy R., Donovan B., Law M.G., Regan D.G. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex. Transm. Dis. 2013; 40(11): 833-5.
36. Белоцерковцева Л.Д., Майер Ю.И., Коваленко Л.В. Репродуктивное поведение подростков и опыт профилактики ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(1): 92-100. [Belotserkovtseva L.D., et al. Adolescent reproductive behavior and experience in the prevention of HPV-associated diseases in KhMAO-Yugra. Questions of gynecology, obstetrics and perinatology 2018; 17 (1): 100-8. (in Russ.]
37. Зароченцева Н.В., Белая Ю.М., Джиджихия Л.К. Вакцинопрофилактика рака шейки матки и заболеваний, ассоциированных с вирусом папилломы человека: вопросы и ответы. Российский вестник акушера-гинеколога. 2017; 17(5): 23-8. [Zarochentseva N.V., Belaya Y.M., Dzhidzhikhia L.K. Vaccinator prevention of cervical cancer and diseases associated with human papillomavirus: questions and answers. Rossiyskiyvestnikakushera-ginekologa. 2017; 17(5): 23-28. (in Russian)]
38. Esquerré M., Bouillette-Marussig M., Goubier A., Momot M., Gonindard C., Keller H. et al. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. PLoS One. 2017;12(3): e0174038.
39. Зардиашвили М.Д., Франкевич В.Е., Назарова Н.М., Бугрова А.Е., Кононихин А.С., Бржозовский А.Г., Стародубцева Н.Л., Асатурова А.В., Сухих Г.Т. Характеристика изменений протеомного состава цервиковагинальной жидкости при заболеваниях шейки матки, ассоциированных с ВПЧ-инфекцией. Акушерство и гинекология. 2017; 4: 88-94. [Zardiashvili M.D., Frankevich V.E., Nazarova N.M., Bugrova A.E., Kononikhin A.S., Brzhozovsky A.G., Starodubtseva N.L., Asaturova A.V., Sukhikh G.T. Characteristic changes in the proteomic composition of cervicovaginal fluid in cervical diseases associated with HPV infection. Obstetrics and gynecology. 2017; 4: 88-94.(in Russian)]

Received 02.02.2019

Accepted 22.02.2019